[1]张淑波.瑞舒伐他汀钙强化治疗对非ST段抬高型急性冠状动脉综合征高危患者血清脂蛋白相关磷脂酶A2及炎性因子水平的影响[J].新乡医学院学报,2016,33(8):704-706.[doi:10.7683/xxyxyxb.2016.08.015]
　ZHANG Shu-bo.Effect of rosuvastatin calcium intensive therapy levels of serum lipoprotein-associated phospholipase A2 & inflammatory factors in patients high-risk non-ST-segment elevation acute coronary syndrome[J].Journal of Xinxiang Medical University,2016,33(8):704-706.[doi:10.7683/xxyxyxb.2016.08.015]
点击复制

瑞舒伐他汀钙强化治疗对非ST段抬高型急性冠状动脉综合征高危患者血清脂蛋白相关磷脂酶A2及炎性因子水平的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
33
期数:
2016年8
页码:
704-706
栏目:
临床研究
出版日期:
2016-07-27

文章信息/Info

Title:
Effect of rosuvastatin calcium intensive therapy levels of serum lipoprotein-associated phospholipase A2 & inflammatory factors in patients high-risk non-ST-segment elevation acute coronary syndrome
作者:
张淑波
（黄冈市中心医院药剂科，湖北　黄冈　438000）
Author(s):
ZHANG Shu-bo
（Department of Pharmacy，Huanggang Central Hospital，Huanggang 438000，Hubei Province，China）
关键词:
瑞舒伐他汀钙; 强化治疗; 脂蛋白相关磷脂酶A2; 肿瘤坏死因子-α; 白细胞介素-6; C反应蛋白; 非ST段抬高型急性冠状动脉综合征
Keywords:
rosuvastatin calcium; intensive therapy; lipoprotein-associated phospholipase A2; tumor necrosis factor-α; interleukin-6; C-reactive protein; non-ST-segment elevation acute coronary syndrome
分类号:
R541
DOI:
10.7683/xxyxyxb.2016.08.015
文献标志码:
A
摘要:
目的　探讨瑞舒伐他汀钙强化治疗对非ST段抬高型急性冠状动脉综合征（NSTE-ACS）高危患者血清脂蛋白相关磷脂酶A2（Lp-PLA2）及炎性因子水平的影响。方法　选择2013年7月至2015年2月在黄冈市中心医院住院治疗的NSTE-ACS高危患者86例，根据治疗方法分为观察组和对照组，每组43例。对照组患者给予瑞舒伐他汀钙标准治疗（10 mg），观察组患者给予瑞舒伐他汀钙强化治疗（20 mg）；分别于治疗前及治疗48 h后测定2组患者血清Lp-PLA2、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、C反应蛋白（CRP）、丙氨酸氨基转移酶（ALT）和天门冬氨酸氨基转移酶（AST）水平；治疗后随访3个月，记录不良反应发生情况。结果　治疗前2组患者血清Lp-PLA2、CRP、TNF-α及IL-6水平比较差异均无统计学意义（P>0.05）。治疗后2组患者血清Lp-PLA2、CRP、TNF-α及IL-6水平均显著低于治疗前（P<0.05）；治疗后观察组患者血清Lp-PLA2、CRP、TNF-α及IL-6水平均显著低于对照组（P<0.05）。治疗前及治疗后2组患者血清ALT、AST水平比较差异均无统计学意义（P>0.05），2组患者治疗后血清ALT、AST水平与治疗前比较差异均无统计学意义（P>0.05）。2组患者均未出现肌痛、横纹肌溶解、过敏等不良反应。结论　瑞舒伐他汀钙强化治疗NSTE-ACS高危患者能够有效减轻机体炎症反应，稳定动脉粥样硬化斑块，且有较高的安全性。
Abstract:
Objective　To explore the effect of rosuvastatin calcium intensive therapy on the levels of serum lipoprotein-associated phospholipase A2（Lp-PLA2） and inflammatory factors in patients with high-risk non-ST-segment elevation acute coronary syndrome（NSTE-ACS）.Methods　A total of 86 patients with high-risk NSTE-ACS were selected in Huanggang Central Hospital from July 2013 to February 2015.All the patients were divided into observation group and control group according to therapeutic method，43 patients in each group.The patients in control group were treated with 10 mg rosuvastatin calcium standard therapy，and the patients in observation group were treated with 20 mg rosuvastatin calcium intensive therapy.The levels of serum Lp-PLA2，tumor necrosis factor-α（TNF-α），interleukin-6（IL-6），C-reactive protein（CRP），alanine transarninase（ALT） and aspartate aminotransferase（AST） were detected before treatment and 48 hours after treatment.All the patients were followed up for three months，and the adverse reactions of patients were recorded.Results　There was no significant difference in the levels of serum Lp-PLA2，CRP，TNF-α and IL-6 between the two groups before treatment（P>0.05）.The levels of serum Lp-PLA2，CRP，TNF-α and IL-6 after treatment were significantly lower than those before treatment in the two groups（P<0.05）.The levels of serum Lp-PLA2，CRP，TNF-α and IL-6 in observation group were significantly lower than those in control group after treatment（P<0.05）.There was no significant difference in the level of serum ALT and AST between the two groups before and after treatment（P>0.05）.There was no significant difference in the level of serum ALT and AST between the two groups before and after treatment（P>0.05）.Myalgia，rhabdomyolysis and allergies were not found in the two groups.Conclusion　Rosuvastatin calcium intensive therapy can effectively reduce the inflammatory reaction and stable the atherosclerotic plaque with higher safety in high-risk NSTE-ACS patients.

参考文献/References:

［1］　IONOMIDIS I，MICHALAKEAS C A，LEKAKIS J，et al.The role of lipoprotein associated phospholipase A2（Lp-PLA2） in cardiovascular disease［J］.Rev Recent Clin Trials，2011，6（2）：108-113.
［2］　李书国，邓娟娟，朱慧铭.瑞舒伐他汀强化治疗对急性冠脉综合征血运重建术后血脂及C反应蛋白的影响［J］.心血管康复医学杂志，2011，20（4）：377-380.
［3］　王锐，丁良才，盛柯杰，等.瑞舒伐他汀对急性冠脉综合征合并心律失常患者炎性因子的影响［J］.江苏大学学报（医学版），2014，24（1）：68-71.
［4］　段霄燕，任晓兰，余建中.瑞舒伐他汀对急性冠状动脉综合征患者介入后血管内皮功能、血清炎症因子和预后的影响［J］.重庆医学，2015，44（1）：52-54.
［5］　AMERICAN COLLEGE OF CARDIOLOGY，AMERICAN HEART ASSOCIATION.Guidelines of the American College of Cardiology/American Heart Association 2007 for the management of patients with unstable angina/non-ST-elevation myocardial infarction［J］.Kardiologiia，2008，48（9）：66-86.
［6］　赵文娟，李庆民，孙广利，等.瑞舒伐他汀对急性冠脉综合征患者血清IMA及hs-CRP的影响［J］.中国实用神经疾病杂志，2012，15（1）：22-24.
［7］　张宗玉.瑞舒伐他汀对急性冠脉综合征患者血清高敏C反应蛋白和肿瘤坏死因子α的影响［J］.实用心脑肺血管病杂志，2011，19（12）：2051-2052.
［8］　DOHI T，MIYAUCHI K，OKAZAKI S，et al.Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome［J］.Atherosclerosis，2011，219（2）：907-912.
［9］　WANG Z，DAI H，XING M，et al.Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes［J］.J Cardiovasc Pharmacol Ther，2013，18（4）：327-333.
［10］　赵艳辉，冯玲.强化瑞舒伐他汀钙治疗对非ST段抬高急性冠脉综合征患者的影响［J］.中国药房，2015，26（14）：1968-1970.
［11］　裴志强，吴从印，杨冰，等.LP-PLA2在非ST段抬高急性冠脉综合征患者危险分层及近期预后评估中的作用［J］.中国急诊医学杂志，2013，22（2）：185-189.
［12］　苗艳，阎磊，朱清，等.血清脂蛋白相关磷脂酶A2水平对糖尿病肾病患者尿白蛋白排泄率和血肌酐的影响［J］.新乡医学院学报，2015，32（6）：522-525.

相似文献/References:

[1]蒋铁桥,张群,杨刚毅,等.短期胰岛素泵强化治疗对初诊2型糖尿病患者β细胞功能的影响[J].新乡医学院学报,2010,27(04):000.
[2]刘　成.不同剂量瑞舒伐他汀钙对脑梗死合并高脂血症患者血脂水平、血管内皮功能及神经功能的影响[J].新乡医学院学报,2021,38(5):453.[doi:10.7683/xxyxyxb.2021.05.012]
　LIU Cheng.Effect of different doses of rosuvastatin calcium on blood lipid level,vascular endothelial function and neurological function of patients with cerebral infarction and hyperlipidemia[J].Journal of Xinxiang Medical University,2021,38(8):453.[doi:10.7683/xxyxyxb.2021.05.012]
[3]彭　敏,闫　超.瑞舒伐他汀钙对老年慢性心力衰竭患者氧化-抗氧化系统及血管内皮细胞功能的影响[J].新乡医学院学报,2017,34(8):751.[doi:10.7683/xxyxyxb.2017.08.024]
　PENG Min,YAN Chao.Effects of rosuvastatin calcium on oxidation-antioxidation system and vascular endothelial cell function in elderly patients with chronic heart failure[J].Journal of Xinxiang Medical University,2017,34(8):751.[doi:10.7683/xxyxyxb.2017.08.024]

更新日期/Last Update: 2016-08-05